EGFR targeted therapy for lung cancer: are we almost there?

by Metro, Giulio
Published in Transl Lung Cancer Res (2018)

Advances on EGFR mutation for lung cancer

by Metro, Giulio, Crinò, Lucio
Published in Transl Lung Cancer Res (2012)

Preface on “Emerging treatment options for brain metastases from non-small cell lung cancer”

by Metro, Giulio, Chiari, Rita
Published in Transl Lung Cancer Res (2016)

Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy

by Tazza, Marco, Metro, Giulio
Published in J Thorac Dis (2017)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

by Addeo, Alfredo, Metro, Giulio
Published in Drugs Context (2018)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?

by Metro, Giulio, Signorelli, Diego
Published in Lung Cancer Manag (2020)

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

by Metro, Giulio, Di Maio, Massimo
Published in Transl Lung Cancer Res (2018)

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

by Metro, Giulio, Di Maio, Massimo
Published in Transl Lung Cancer Res (2018)

Years of sorafenib investigation in advanced non-small cell lung cancer: is there a ‘NExUS’ linking an unsuccessful treatment and a potentially active one?

by Metro, Giulio, Minotti, Vincenzo, Crinò, Lucio
Published 2012

Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?

by Chiari, Rita, Sidoni, Angelo, Metro, Giulio
Published in J Thorac Dis (2018)

Melanosis coli or ischaemic colitis? That is the question

by Ricciuti, Biagio, Leone, Maria Comasia, Metro, Giulio
Published in BMJ Case Rep (2015)

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken opt...

by Ricciuti, Biagio, Lamberti, Giuseppe, Roila, Fausto, Metro, Giulio
Published in Transl Lung Cancer Res (2019)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-...

by Addeo, Alfredo, Banna, Giuseppe Luigi, Metro, Giulio, Di Maio, Massimo
Published in Front Oncol (2019)

Non-coding RNAs in lung cancer

by Ricciuti, Biagio, Mecca, Carmen, Crinò, Lucio, Baglivo, Sara, Cenci, Matteo, Metro, Giulio
Published in Oncoscience (2014)

Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review

by Metro, Giulio, Baglivo, Sara, Moretti, Riccardo, Bellezza, Guido, Sidoni, Angelo, Roila, Fausto
Published in Oncol Ther (2020)

Targeting EGFR and ALK in NSCLC: current evidence and future perspective

by Bennati, Chiara, Paglialunga, Luca, Ricciuti, Biagio, Metro, Giulio, Marcomigni, Luca, Gili, Alessio, Crinò, Lucio
Published in Lung Cancer Manag (2016)

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

by Baglivo, Sara, Ludovini, Vienna, Moretti, Riccardo, Bellezza, Guido, Sidoni, Angelo, Roila, Fausto, Metro, Giulio
Published in Oncol Ther (2020)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

by Ricciuti, Biagio, Baglivo, Sara, Paglialunga, Luca, De Giglio, Andrea, Bellezza, Guido, Chiari, Rita, Crinò, Lucio, Metro, Giulio
Published in Ther Adv Med Oncol (2017)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination wit...

by Fabi Alessandra, Russillo Michelangelo, Ferretti Gianluigi, Metro Giulio, Nisticò Cecilia, Papaldo Paola, De Vita Ferdinando, D’Auria Giuliana, Vidiri Antonello, Giannarelli Diana, Cognetti Francesco
Published 2012-10-01

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination wit...

by Fabi, Alessandra, Russillo, Michelangelo, Ferretti, Gianluigi, Metro, Giulio, Nisticò, Cecilia, Papaldo, Paola, De Vita, Ferdinando, D’Auria, Giuliana, Vidiri, Antonello, Giannarelli, Diana, Cognetti, Francesco
Published 2012